Combinatorial Cancer Immunotherapies.

[1]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[2]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[3]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[4]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Leachman,et al.  A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma. , 2015 .

[6]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[7]  G. Giaccone,et al.  Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). , 2015 .

[8]  I. Puzanov,et al.  Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. , 2015 .

[9]  P. Ascierto,et al.  Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. , 2015 .

[10]  L. Sequist,et al.  Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. , 2015 .

[11]  R. Dummer,et al.  A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. , 2015 .

[12]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[13]  K. Steele,et al.  Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. , 2015 .

[14]  J. Rudra,et al.  NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade , 2015, Journal of Immunotherapy for Cancer.

[15]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[18]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[20]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[21]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[22]  C. Drake,et al.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.

[23]  Kunwei Shen,et al.  The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis , 2014, PloS one.

[24]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[25]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[26]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[27]  H. Kohrt,et al.  Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series , 2014 .

[28]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[29]  L. Zitvogel,et al.  Trial watch: IDO inhibitors in cancer therapy , 2014, Oncoimmunology.

[30]  J. Wolchok,et al.  Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Gibney,et al.  Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. , 2014 .

[32]  S. Gettinger,et al.  Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. , 2014 .

[33]  S. Gettinger,et al.  Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). , 2014 .

[34]  E. Plimack,et al.  Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). , 2014 .

[35]  P. Ascierto,et al.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.

[36]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[37]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[38]  Shulan Zhang,et al.  PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer , 2014, PloS one.

[39]  H. Ueno,et al.  CD8+ and FOXP3+ Tumor-Infiltrating T Cells Before and After Chemoradiotherapy for Rectal Cancer , 2014, Annals of Surgical Oncology.

[40]  Lei Lu,et al.  Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs , 2014, Journal of Translational Medicine.

[41]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[42]  C. Drake,et al.  Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses , 2013, BioMed research international.

[43]  William L. Redmond,et al.  Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity , 2013, Cancer Immunology Research.

[44]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[45]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[46]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[47]  S. Strober,et al.  Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. , 2013, Clinical immunology.

[48]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[49]  J. Werner,et al.  Low‐dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer , 2013, International journal of cancer.

[50]  Michael R. Green,et al.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.

[51]  Masashi Kato,et al.  Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model , 2013, The Journal of Immunology.

[52]  E. Jaffee,et al.  Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. , 2012, Cancer research.

[53]  M. van den Broek,et al.  Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation , 2012, The Journal of Immunology.

[54]  Antoni Ribas,et al.  Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.

[55]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[56]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  B. Kwon,et al.  Immunotherapy of Cancer with 4-1BB , 2012, Molecular Cancer Therapeutics.

[58]  Xiaodong Li,et al.  Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer , 2012, Cancer Immunology, Immunotherapy.

[59]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[60]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[61]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[62]  A. Sevko,et al.  Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation , 2012, Cancer Immunology, Immunotherapy.

[63]  H. Moch,et al.  γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo , 2011, PloS one.

[64]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[65]  M. Smyth,et al.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. , 2011, Cancer research.

[66]  J. Allison,et al.  Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production , 2011, PloS one.

[67]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[68]  Yijun Wang,et al.  Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function , 2011, Journal of immunotherapy.

[69]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[70]  T. Okazaki,et al.  PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice , 2011, The Journal of experimental medicine.

[71]  B. Kwon,et al.  4-1BB signaling beyond T cells , 2011, Cellular and Molecular Immunology.

[72]  D. Speiser,et al.  The CD4-like molecule LAG-3, biology and therapeutic applications , 2011, Expert opinion on therapeutic targets.

[73]  B. Baban,et al.  Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. , 2010, Immunity.

[74]  Todd M. Allen,et al.  Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. , 2010, The Journal of clinical investigation.

[75]  J. Wolchok,et al.  Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. , 2010, Current opinion in investigational drugs.

[76]  A. Carè,et al.  A non‐redundant role for OX40 in the competitive fitness of Treg in response to IL‐2 , 2010, European journal of immunology.

[77]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[78]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[79]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[80]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[81]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  J. Allison,et al.  Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals , 2010, Clinical Cancer Research.

[83]  J. Wolchok,et al.  Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation , 2010, PloS one.

[84]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[85]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[86]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[87]  J. Wolchok,et al.  Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right , 2009, The Journal of Immunology.

[88]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[89]  D. Getnet,et al.  Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1 , 2009, The Journal of Immunology.

[90]  L. Old,et al.  Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. , 2008, Cancer research.

[91]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[92]  J. Kirkwood,et al.  Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) , 2008 .

[93]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[94]  C. Riccardi,et al.  Glucocorticoid-Induced TNFR-Related Protein Lowers the Threshold of CD28 Costimulation in CD8+ T Cells1 , 2007, The Journal of Immunology.

[95]  D. Getnet,et al.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. , 2007, The Journal of clinical investigation.

[96]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[97]  M. Baccarani,et al.  Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. , 2007, Blood.

[98]  Paul Garside,et al.  Reversal of the TCR Stop Signal by CTLA-4 , 2006, Science.

[99]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[100]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[101]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[102]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[103]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[104]  P. Puccetti,et al.  Immunity and Tolerance to Aspergillus Involve Functionally Distinct Regulatory T Cells and Tryptophan Catabolism1 , 2006, The Journal of Immunology.

[105]  P. Saunders,et al.  PD‐L2:PD‐1 involvement in T cell proliferation, cytokine production, and integrin‐mediated adhesion , 2005, European journal of immunology.

[106]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.

[107]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[108]  Robert C. Rose,et al.  Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.

[109]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[110]  B. Dörken,et al.  Costimulation by CD137/4–1BB inhibits T cell apoptosis and induces Bcl‐xL and c‐FLIPshort via phosphatidylinositol 3‐kinase and AKT/protein kinase B , 2005, European journal of immunology.

[111]  M. Colombo,et al.  Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. , 2005, Blood.

[112]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[113]  J. Schlom,et al.  Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.

[114]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[115]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[116]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[117]  I. Ishikawa,et al.  Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells1 , 2004, The Journal of Immunology.

[118]  M. Croft,et al.  Costimulation of CD8 T Cell Responses by OX401 , 2004, The Journal of Immunology.

[119]  K. Sugamura,et al.  Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells1 , 2004, The Journal of Immunology.

[120]  Yoshimasa Tanaka,et al.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.

[121]  D. Vignali,et al.  The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells , 2003, European journal of immunology.

[122]  I. Wang,et al.  Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses , 2003, The Journal of Immunology.

[123]  Sujung Park,et al.  4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11 , 2002, The Journal of Immunology.

[124]  A. Sharpe,et al.  Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation , 2002, European journal of immunology.

[125]  Lieping Chen,et al.  Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1 , 2002, The Journal of Immunology.

[126]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[127]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[128]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[129]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[130]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[131]  J. Madrenas,et al.  CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression1 , 2000, The Journal of Immunology.

[132]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[133]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[134]  A. Khoruts,et al.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. , 1999, Immunity.

[135]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[136]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  J. Allison,et al.  CTLA-4-Mediated inhibition of early events of T cell proliferation. , 1999, Journal of immunology.

[138]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[139]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[140]  P. Linsley,et al.  Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions* , 1996, The Journal of Biological Chemistry.

[141]  A. Barclay,et al.  OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand , 1996, European journal of immunology.

[142]  K. Bennett,et al.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. , 1996, Immunity.

[143]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[144]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[145]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[146]  C. Benoist,et al.  LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. , 1996, International immunology.

[147]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[148]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[149]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[150]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[152]  F. Faure,et al.  Lymphocyte‐activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes , 1994, European journal of immunology.

[153]  M. Seldin,et al.  Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV‐1‐regulated protein gp34. , 1994, The EMBO journal.

[154]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[155]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[156]  G. Freeman,et al.  Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. , 1993, Science.

[157]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[158]  C. Auffray,et al.  Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens , 1992, The Journal of experimental medicine.

[159]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[160]  S. Roman-Roman,et al.  LAG-3, a novel lymphocyte activation gene closely related to CD4 , 1990, The Journal of experimental medicine.

[161]  A. Barclay,et al.  Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes‐‐a molecule related to nerve growth factor receptor. , 1990, The EMBO journal.

[162]  A. Morales,et al.  INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORS , 1976, The Journal of urology.

[163]  M BURNET,et al.  Cancer—A Biological Approach* , 1957, British medical journal.

[164]  M. Burnet.  Cancer—A Biological Approach , 1957, British medical journal.

[165]  Mole Rh.  Whole body irradiation; radiobiology or medicine? , 1953 .

[166]  J. Wolchok,et al.  Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. , 2013, Cancer immunity.

[167]  T. Lynch,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[168]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[169]  A. J. Crowle.  Delayed hypersensitivity in health and disease , 1962 .